Olmesartan/Amlodipin/Hct Ratiopharm (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipin/Hct Ratiopharm is indicated for hypertension management, acting on the renin‑angiotensin system and vascular smooth‑muscle tone.

• Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with fluid retention: combines vasodilation with diuretic action to improve blood‑pressure control.
• Hypertension in patients requiring multiple mechanisms: provides triple‑mechanism therapy (ARB, calcium‑channel blocker, thiazide diuretic).

• Olmesartan medoxil blocks the binding of angiotensin II to AT‑1 receptors, preventing vasoconstriction. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. Hydrochlorothiazide reduces sodium and water reabsorption in the distal convoluted tubule, decreasing plasma volume. The combined actions produce additive blood‑pressure reduction.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache
• Peripheral edema
• Dizziness
• Flushing
• Fatigue
• Increased urination

Serious or Rare Side Effects

• Angio‑edema
• Severe hypotension
• Electrolyte disturbances (e.g., hyponatremia, hypokalemia)
• Acute kidney injury
• Liver enzyme elevation
• Blood dyscrasias

When prescribing Olmesartan/Amlodipin/Hct Ratiopharm, clinicians should consider several safety aspects.

• Renal function monitoring: assess baseline creatinine and eGFR, especially in patients with chronic kidney disease.
• Electrolyte assessment: check serum potassium and sodium levels regularly.
• Pregnancy contraindication: avoid use in pregnancy due to fetal toxicity.
• Concomitant drug review: evaluate for other antihypertensives that may cause additive hypotension.
• Patient education: advise on signs of low blood pressure and when to seek medical help.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Olmesartan/Amlodipin/Hct Ratiopharm may interact with several medicines; careful review is required.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, aliskiren) – increased risk of renal impairment and hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may raise amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihypertensive effect and affect renal function.
• Lithium – increased lithium concentrations, risk of toxicity.
• Digoxin – heightened risk of digoxin toxicity when combined with diuretics.
• High‑dose potassium supplements – may exacerbate hyperkalaemia.
• Alcohol – additive vasodilatory effect, may increase dizziness.